Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that...
Quanterix Corporation (Nasdaq: QTRX) , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial...
Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to...
Agreement supports the identification of patients eligible for Alzheimer’s disease biomarker testing through Tempus Next and enables neurologists to order LucentAD® Complete on Tempus’ clinical ordering...
Quanterix Corporation (Nasdaq: QTRX) , a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call...
Novel Assay, Developed on Akoya PhenoImager HT Platform with Opal Chemistry, Becomes First to Predict Both Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer...
The Content Innovation Engine brings together Akoya's spatial biology platform and Quanterix's immunoassay infrastructure to systematically unlock cancer biology and accelerate the path toward clinical...
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Company’s 2026 annual meeting of...
Reports $43.9 million in revenue and cash balance of $122 million Company expects to achieve cash flow breakeven during 2026
Collaboration Aims to Expand Access to Early Detection of Potential Disease Marker